Global VRE and MRSA Antibiotics Market Size, Share and Trends Analysis Report, By Type (Vancomycin, Teicoplanin, Linezolid, and Daptomycin) and By Distribution Channel (Hospital Pharmacies and Retail Drug Stores) Forecast (2022-2028)

The global VRE and MRSA antibiotics market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period (2022-2028). VRE and MRSA antibiotics are the medication that can be used for the treatment of infection caused due to vancomycin-resistant enterococci (VRE) and methicillin-resistant staphylococcus aureus (MRSA). VRE and MRSA are antibiotic-resistant bacterias that can cause serious infections and can be spread due to contact. The major factor attributing to the growth of the global VRE and MRSA antibiotics market is the rising prevalence of MRSA infection. According to the Centers for Disease Control and Prevention (CDC), around 5% of the patients coming to hospitals in the US carry MRSA bacteria on their skin or in their nose. It is caused due to sharing of personal items including towels, razors that have been touched by the infected person.

In addition, the increasing prevalence of VRE infection has increased the demand for VRE and MRSA antibiotics. According to the AR Threat Report published by the Centers for Disease Control and Prevention (CDC) in 2019, around 54,500 patients are diagnosed with VRE infections among the hospitalized patients in the US alone with mortality of around 5,400 due to serious VRE infections. The patients who undergo surgical procedures are at the maximum risk of getting infected by VRE bacteria. Thus, the increasing number of surgical procedures are also increasing VRE infections in hospitalized patients. According to  World Health Organisation (WHO), an estimation of around 234.2 million major surgical procedures are done each year globally.

Several developments and FDA approvals are also attributed to the market growth. For instance, in June 2019, ANI Pharmaceuticals got approval from the US Food and Drug Administration (FDA) for the oral suspension of vancomycin hydrochloride for the treatment of various infections including VRE and MRSA. The oral suspension is offered in 80 mL, 150 mL, and 300 mL packs. Similarly, in September 2020, Xellia Pharmaceuticals ApS got the approval for 3 dosage forms for its Vanco Ready. Vanco Ready is the ready-to-use premixed vancomycin injection bag by Xellia Pharmaceuticals. The three approved dosage forms are 750mg in 150ml, 1.25g in 250ml, and 1.75g in 350ml.

Some major players in the market include Pfizer Inc., Sanofi SA, Eli Lilly & Co., Merck & Co. Inc., Xellia Pharmaceuticals ApS, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in May 2019, Civica Rx, a nonprofit drug manufacturer and Danish Drugmaker entered into an agreement for the increased production of injected forms of vancomycin and daptomycin. The goal of this agreement is to increase the availability of these two short-supply antibiotics among patients that can be used for the treatment of VRE and MRSA infections.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc., Sanofi SA, Eli Lilly & Co., Merck & Co. Inc., and Xellia Pharmaceuticals ApS, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global VRE and MRSA Antibiotic  Market Report by Segment

By Type

• Vancomycin
• Teicoplanin
• Linezolid
• Daptomycin

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores

Global VRE and MRSA Antibiotic  Market Report by Region

North America

• The US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa